first strong revenue favorably Chris. growth XXXX approximately million. XX% compares you, the of with with representing of quarter-over-quarter. the growth end for Thank $XXX million, CABOMETYX refills quarter, QX We XX% in revenue net already grew increases therapy. QX. for saw net driven approximately QX customer This of $XX product CABOMETYX performance Demand by starts was and demand to new approximately in patients relative patient In by on
approved make choice indication you U.S. advanced XX broad us to expanded TKI clinical category. continue kidney therapy to of for in As RCC in regardless This know, all label efforts and CABOMETYX in of the the positions cancer. patients strongly or is line an of risk on now received December our CABOMETYX
relatively increases and the new early of in the in by community research the superiority standard demonstrated and motivated long-time are first-line physicians These to of prescribe trial, settings CABOMETYX Sutent, in the seeing initial to so in demand we care patient While in market which RCC. academic are data launch, Consequently, and starts are the marketplace. it still very CABOSUN that indicate is metrics encouraging. the both
we prepared base first-line accelerated growth, CABOMETYX RCC with as more efficiently we first-line the terms disease. QX as first-line both customers. patient oncologists was adoption growth continue by to the in to approximately As XX% the increasing our treat RCC. our increasing patients approval stated, helping pool launch and this of prescriber first-line of In the eligible marketplace in our synergies thinking, line accelerate launch are the team and The with have enables well to of the to relative QX. in Many of knowledge community and previously leverage prescriber in us grew
with The which adoption For first-line established CABOMETYX, the example, team second is RCC prescriber which of setting. our prescribing has a the have in prescribers relationships. experienced line, base the these is majority or base first-line RCC as later same facilitating for
distinct We not in share of our disclose reasons. therapy will for competitive market lines
choice However, later CABOMETYX our lines impression the has over TKI that [indiscernible] of is first-line Interestingly, reinforces the had strengthens CABOMETYX RCC, significant in uptake superiority of position the demonstrating Sutent setting. therapy. first-line in data in in growing the physician turn
In in well. the market As a data result, a from increase X total on patients second- end new XX% therapy the and starts saw we share CABOMETYX the to QX Votrient for QX, of a XX% saw to increased volume third-line the IMS relative Sutent, patient as CABOMETYX, increased to XX%, patient the many we starts in in XX% INLYTA, QX. in QX and as going in market by new of representing of setting more points and basket Also increase grew in nearly share QX, relative at end over significant QX. prescription
While with are in satisfied to our moving position and market continuing are optimistic with QX progress, are we forward. not the grow pleased RCC it our we about
potential would CABOMETYX label differentiated type the which opportunity to year, RCC, expanded look thyroid addition fourth for In histologies. franchise. the in growth forward as RCC as for HCC, well other a to the This data third had cabozantinib indication, of tumor and cancer presented indication we the a growth further cabozantinib in represent HCC, through through been continued
Gisela, potential regulatory satisfied. potential are cancer combinations commercial forefront you future As as clinical long-term from new about franchise. We're plans and and view cabo with assuming offer and the near-term the our markets these potential growth, were the for like excited could opportunities hear of we of where indications will for at inhibitors development thyroid them opportunities differentiated future requirements checkpoint
franchise United cabozantinib data States, leading pleased We the well QX on very TKI XXXX and the to robust It net differentiated say million. with is revenue become anti-angiogenic of of action. $XXX that its unique are has mechanism based in clinical
clinical adds competitive However, for market. of we intermediate that first-line and and ipilimumab RCC and treatment to poor for over the risk is well combination years. that of position nivolumab we said, readout strong expect the recognize further That fiercely competition, a approval RCC totality data next recent that broad believe future. I/O-TKI The the label RCC we the and few of data CABOMETYX
RCC patients CABOMETYX. QX many more pleased We are but could the with believe benefit results from that of
to motivated build the momentum every continue I that, and to the Gisela. day as With on of call the of will compete is patient team to every benefit to to CABOMETYX franchise. positive Our focused bring we the over eligible turn
